COVAC 1 - The Imperial College London vaccine is comprised of SARS-CoV-2 spike protein self-amplifying RNA that is packaged into tiny droplets of fat.

1

https://theconversation.com/coronavirus-how-countries-aim-to-get-the-vaccine-first-by-cutting-opaque-supply-deals-143366

https://theconversation.com/coronavirus-how-countries-aim-to-get-the-vaccine-first-by-cutting-opaque-supply-deals-143366

Other approaches are possible. Along with the UK funding package for the University of Oxford, the government also allocated £18.5 million to Imperial College London for a different COVID-19 vaccine project. Having completed clinical trials, Imperial announced on July 17 that it was proceeding to the next trial phase, involving 105 participants aged 18-75.

Imperial has formed a new social enterprise, VacEquity Global Health, to rapidly develop this vaccine and distribute it as widely as possible in the UK and overseas, including to low- and middle-income countries. This is in partnership with Morningside Ventures, a fund based in Hong Kong that invests in companies for the public good.

Rather than partnering with one company, the Imperial model envisages links with multiple manufacturers and waiving royalties and charging a modest amount for its vaccine. Agreements to purchase, manufacture and distribute the vaccine are still being negotiated.

It remains to be seen whether this social enterprise approach proves more successful in achieving equitable access to COVID-19 vaccines in the longer term, but it seems more in line with how we should be tackling this crisis.

Public money invested in publicly funded institutions should be treated as a public good, not as private intellectual property rights to be licensed and traded by private companies without full and proper public scrutiny.

#VacEquityGlobalHealth

2

https://biorender.com/covid-vaccine-tracker/details/v-0034/rna-sarna

https://biorender.com/covid-vaccine-tracker/details/v-0034/rna-sarna

COVAC 1

Vaccine
Phase I/II

The Imperial College London vaccine is comprised of SARS-CoV-2 spike protein self-amplifying RNA that is packaged into tiny droplets of fat.

Upon vaccination into muscle, host cells uptake this mixture and produce the viral spike protein.

Some of these proteins are displayed on the surface of the cells, where the host’s immune system can recognize them as foreign antigens and generate an antibody response against them.

The vaccinated individual will thus have circulating antibodies against the viral spike protein which will theoretically protect them from infection with the SARS-CoV-2 virus.

Organizations
Imperial College London, Morningside Ventures
Countries Involved
United Kingdom
China
Trial Participants

Phase 1/2: 300
Clinical Trial Number
IRAS-Number: 279315 CPMS-ID: 46068

#SARSCoV2 #CoVac1 #saRNA

3

https://www.instagram.com/p/CDcCz70HTjJ/

https://www.instagram.com/p/CDcCz70HTjJ/

[#RFKJr makes a valid point. Perhaps we shouldn't trust the process.]